Autonomize AI

The AI is the product. Autonomize sells the Autonomize Intelligence Platform: 160+ ready to deploy agents and workflows for prior authorization, appeals and grievances, payment integrity, care management and chart review, built in AI Studio, grounded in a Knowledge Center context graph of 10 million+ clinical, regulatory and coverage concepts, and monitored in a Command Center. The connectors, studio and monitoring exist to run the agents; there is no system of record or services business beneath them.

The oversight structure is described with the thresholds missing. The platform page describes 'human in the lead' design: hard constraints prevent high risk auto actions, complex cases escalate with the clinical reasoning intact, and auto approvals and auto prompts run with full audit trails; the Command Center traces human review on each run. The home page's line that the AI 'doesn't just assist. It acts' makes the boundary matter. What is not published is which actions count as high risk, what the confidence threshold for an auto approval is, or whether any agent can prepare or influence a denial.

The architecture is described in general terms with nothing identified. Autonomize describes agents built in AI Studio with testing and version control, grounded in a context graph of 10 million+ clinical, regulatory and coverage concepts that updates with every decision, and healthcare native AI as opposed to general purpose models. No model or model family, accuracy figure per agent, evaluation method or model card is published.

The architecture is described and no model provider is named. Autonomize describes agents, a context graph and connectors, distribution through Microsoft's marketplaces and the ServiceNow Store, and a vendor risk assessment in its trust center, but names no model provider, host or subprocessor, and publishes no subprocessor list.

Named deployments with dated outcome figures, short of independent evaluation. Autonomize's case study dated 24 February 2026 reports that Altais Health Solutions cut prior authorization review time by 45 percent, turnaround time by 63 percent and manual errors by 54 percent, with a 50 percent lift in clinical productivity.

Other case studies cover a Fortune 100 health plan (prior authorization processing time down 55 percent) and a national Medicare Advantage plan (appeals case preparation time down 80 percent), unnamed. Executives at The Cigna Group, Molina Healthcare and Elevance Health are quoted, and the home page reports clinicians accepted 98 percent of AI generated information. None states a baseline method or is independently evaluated.

General assurances that do not answer the questions AI raises. Autonomize's trust center lists SOC 2 and HIPAA reports and a data retention, data privacy and encryption policy set, all private documents available on request; nothing is published about retention periods, de identification or training use.

The platform page describes a self learning knowledge system updated with every decision the platform processes, and customers include competing health plans, provider organizations and life sciences companies, so whether one customer's decisions shape agents serving another is the question. Safety engineering is described only as hard constraints on high risk auto actions.

Compliance is claimed without the document behind it. Autonomize's trust center lists HIPAA reports for 2023 to 2025 and a data processing agreement as private documents available on request, and its privacy policy (effective 1 January 2025) covers the website and does not mention protected health information or business associate status. The platform handles clinical notes, faxes and claims for health plans and providers, which makes it a business associate. Life sciences work may run under different authorizations, and the published material does not say how the agreement applies to it.

A recognized certification is named, with the artifacts behind a request. Autonomize's trust center (trust.autonomize.ai) lists SOC 2 reports for each year from 2023 to 2026, a penetration test report, risk assessments and a full policy set, all as private documents a buyer requests access to; the report type is not shown.

No device claim is made and the product is scoped accordingly: the agents inform coverage, payment and administrative determinations rather than diagnosis or treatment. The regulatory exposure sits in payer regulation and is moving: CMS interoperability and prior authorization requirements taking effect in 2026, and state laws restricting or conditioning AI involvement in coverage decisions. Autonomize states no position on either, and no utilization management accreditation is claimed, so a plan buying agentic prior authorization carries the delegation oversight itself.

Governance is committed to in product language, with tooling and no evaluation. The platform page describes deploying agents 'with governance in place', testing and version control in AI Studio, and a Command Center that monitors AI performance and traces each run from input to output including human review; the trust center speaks of oversight and accountability. No bias evaluation, subgroup results or model behavior review is published. On the payer side, automating an approval is low risk and influencing a denial is not; the platform says hard constraints prevent high risk auto actions without saying what they are.

Mechanisms exist and nothing stands behind them. The platform keeps full audit trails, the Command Center traces each run from input to output including human review, and the Knowledge Center grounds each action in the customer's guidance with a path back to its sources, so a reviewer or plan can reconstruct and challenge an output. The home page reports that clinicians accepted 98 percent of AI generated information, which is an acceptance rate, not an error rate. No accuracy figure with a denominator, warranty, indemnity or correction commitment is published.

Integration is claimed with no system named. The platform page reports 50+ prebuilt connectors for EHRs, claims systems, FHIR APIs and legacy inputs, and says agents interface with a plan's existing prior authorization and medical policy systems without changing them; a payment integrity application is listed in the ServiceNow Store and products are distributed through Microsoft's marketplaces. ServiceNow and marketplaces are distribution, not record systems, and no EHR or claims platform is named.

A single hosted option with the location implied. Autonomize describes cloud delivery, activation in days, and distribution through Microsoft's marketplaces; no region, residency commitment or customer hosted option is published, and its trust center lists a network diagram only as a private document. Whether marketplace availability means the platform can run in the customer's own cloud tenancy would change the data posture materially.

No price is published and the posture is discoverable. Autonomize sells enterprise agreements in three shapes: deploy its 160+ ready made agents, co-design workflows with its engineers, or a full transformation partnership. It also distributes through Microsoft's marketplaces and the ServiceNow Store, where listings sometimes carry transactable pricing.

Coverage is named with validation behind part of it. Autonomize serves health plans first, with provider organizations and life sciences, across prior authorization, appeals and grievances, payment integrity, care management and chart review. Named validation covers health plan and physician group prior authorization (Altais case study; executives quoted at Cigna, Molina and Elevance), and the platform page says three of the five largest US health enterprises run it in production. No outcome is published for life sciences or by service category.